pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
ppublish
Résumé
Identifying prognostic biomarkers to predict clinical outcomes in stage I and II cutaneous melanomas could guide the clinical application of adjuvant and neoadjuvant therapies. We aimed to investigate the prognostic value of phosphorylated signal transducer and activator of transcription 5 (pSTAT5) as a biomarker in early-stage melanoma. This study evaluated all initially staged Ib and II melanoma patients undergoing sentinel node biopsy at a tertiary centre in Brisbane, Australia between 1994 and 2007, with survival data collected from the Queensland Cancer Registry. Primary melanoma tissue from 189 patients was analysed for pSTAT5 level through immunohistochemistry. Cox regression modelling, with adjustment for sex, age, ulceration, anatomical location, and Breslow depth, was applied to determine the association between pSTAT5 detection and melanoma-specific survival. Median duration of follow-up was 7.4 years. High pSTAT5 detection was associated with ulceration and increased tumour thickness. However, multivariate analysis indicated that high pSTAT5 detection was associated with improved melanoma-specific survival (hazard ratio: 0.15, 95% confidence interval: 0.03-0.67) as compared to low pSTAT5 detection. This association persisted when pSTAT5 detection was limited to immune infiltrate or the vasculature, as well as when sentinel node positivity was accounted for. In this cohort, staining for high-pSTAT5 tumours identified a subset of melanoma patients with increased survival outcomes as compared to low-pSTAT5 tumours, despite the former having higher-risk clinicopathological characteristics at diagnosis. pSTAT5 is likely an indicator of local immune activation, and its detection could represent a useful tool to stratify the risk of melanoma progression.
Identifiants
pubmed: 37890182
doi: 10.1097/CMR.0000000000000915
pii: 00008390-202312000-00008
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
506-513Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al.; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:472–492.
Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012; 30:1462–1467.
Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (≤1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol 2015; 135:1190–1193.
Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013. J Am Acad Dermatol 2017; 76:258–263.
Claeson M, Baade P, Brown S, Soyer HP, Smithers BM, Green AC, et al. Clinicopathological factors associated with death from thin (≤ 1·00 mm) melanoma. Br J Dermatol 2020; 182:927–931.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics: update 2022. Eur J Cancer 2022; 170:236–255.
Lideikaitė A, Mozūraitienė J, Letautienė S. Analysis of prognostic factors for melanoma patients. Acta Med Litu 2017; 24:25–34.
Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther 2019; 20:1366–1379.
Eguchi MM, Elder DE, Barnhill RL, Piepkorn MW, Knezevich SR, Elmore JG, et al. Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality. Cancer 2022; 129:89–97.
Claeson M, Tan SX, Lambie D, Brown S, Walsh MD, Baade PD, et al. The association between BRAF-V600E mutations and death from thin (≤1.00 mm) melanomas: a nested case–case study from Queensland, Australia. J Eur Acad Dermatol Venereol 2023. 37:e1168–e1172.
Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012; 30:2678–2683.
Yang J, Lian JW, Chin Y-P, Wang L, Lian A, Murphy GF, et al. Assessing the prognostic significance of tumor-infiltrating lymphocytes in patients with melanoma using pathologic features identified by natural language processing. JAMA Netw Open 2021; 4:e21263–e237-e.
Berry S, Giraldo NA, Green BF, Cottrell TR, Stein JE, Engle EL, et al. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science 2021; 372:eaba2609.
Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, et al. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. Oncoimmunology 2019; 8:e1537581.
Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol Biosyst 2006; 2:536–550.
Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal 2017; 15:23.
Lin J-X, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 2000; 19:2566–2576.
Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007; 102:311–319.
Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, et al. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 2009; 15:4085–4094.
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9:e1001216.
Australian Institute of Health and Welfare. National Death Index. Australian Institute of Health and Welfare; 2018.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496–509.
Smithers BM, Hughes MCB, Beesley VL, Barbour AP, Malt MK, Weedon D, et al. Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk of spread, in Queensland, Australia. J Surg Oncol 2015; 112:359–365.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30:582–588.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2022. Eur J Cancer 2022; 170:256–284.
Busch C, Geisler J, Knappskog S, Lillehaug JR, Lønning PE. Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine. J Invest Dermatol 2010; 130:2514–2516.
Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci 1997; 94:7239–7244.
Villarino A, Laurence A, Robinson GW, Bonelli M, Dema B, Afzali B, et al. Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions. Elife 2016; 5:e08384.
Pericle F, Kirken RA, Bronte V, Sconocchia G, DaSilva L, Segal DM. Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J Immunol 1997; 159:2580–2585.
Xiao Q, Wu J, Wang W-J, Chen S, Zheng Y, Yu X, et al. DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 2018; 24:262–270.
Kosan C, Ginter T, Heinzel T, Krämer OH. STAT5 acetylation. JAKSTAT 2013; 2:e26102.
Machiraju D, Moll I, Gebhardt C, Sucker A, Buder-Bakhaya K, Schadendorf D, et al. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α. Melanoma Res 2018; 28:204–210.
Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006; 126:2272–2280.
Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B, et al. Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology 2019; 8:1593806.
Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol 2020; 11:2105.
Verdeil G, Lawrence T, Schmitt-Verhulst A-M, Auphan-Anezin N. Targeting STAT3 and STAT5 in tumor-associated immune cells to improve immunotherapy. Cancers (Basel) 2019; 11:1832.
Bottos A, Gotthardt D, Gill JW, Gattelli A, Frei A, Tzankov A, et al. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun 2016; 7:12258.
Thomas JM. Sentinel lymph node biopsy in malignant melanoma. BMJ 2008; 336:902–903.
Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society Of Clinical Oncology and Society Of Surgical Oncology Clinical Practice guideline update. Ann Surg Oncol 2018; 25:356–377.
Saltman BE, Ganly I, Patel SG, Coit DG, Brady MS, Wong RJ, et al. Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head Neck 2010; 32:1686–1692.
Watts C, Spillane A, Henderson MA, Cust A, Braithwaite J, Gyorki DE, et al. Australian Melanoma Centre of Research Excellence Study G. Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. Med J Aust 2022; 217:208–209.
Varey AHR, Madronio CM, Cust AE, Goumas C, Mann GJ, Armstrong BK, et al. Poor adherence to National Clinical Management Guidelines: a population-based, cross-sectional study of the surgical management of melanoma in New South Wales, Australia. Ann Surg Oncol 2017; 24:2080–2088.
Bownes RJ, Turnbull AK, Martinez-Perez C, Cameron DA, Sims AH, Oikonomidou O. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res 2019; 21:73.